AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Selective Human Sirtuin-2 Inhibitors, the Therapeutic Candidate for Huntington's Disease

Technology Benefits: More potent and selective than previous human sirtuin-2 inhibitors Improved pharmaceutical properties and promising drug candidate

Detailed Technology Description: Selective human sirtuin-2 inhibitors for use in treating Huntington's disease. #therapeutics #cns #huntingtonsdisease

*Abstract: Northwestern researchers have discovered a new series of selective human sirtuin-2 inhibitors which show excellent neuronal protection in the Huntington's disease model. Human sirtuin-2 is a therapeutic target of numerous age-related neuronal degenerative diseases, including Huntington's disease, Parkinson's disease, and Alzheimer's disease. These new compounds were developed using pharmacophere exploration and SAR analysis of a lead compound. This group exhibits improved potency, selectivity and bioavailability and thus are expected to exhibit a promising pharmacological profile.

*Inventors: Richard B. Silverman* Hua Wang Mohammad Khanfar

*Publications: Bioorganic & Medicinal Chemistry Letters. 2012;22(8): 2789-2793.

Country/Region: USA

For more information, please click Here